Additional file 2 of Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study

Additional file 2: Supplemental Figure 1. Selection process of patients for the study

Additional file 1 of Association of tramadol with all-cause mortality, cardiovascular diseases, venous thromboembolism, and hip fractures among patients with osteoarthritis: a population-based study

Additional file 1: Supplemental Table 1. Case definition of all-cause mortality, CVD, VTE, and hip fractures. Abbreviations: CVD, cardiovascular diseases; DVT, deep vein thrombosis; ICD-9, International Classification of Diseases, Ninth Revision; ICD-10, International Classification of Diseases, Tenth Revision; MI, myocardial infarction; PE, pulmonary embolism; VTE, venous thromboembolism

Scores per cycle: Mean (SD).

Scores per cycle: Mean (SD).</p

Mean HUI3 among persons with osteoarthritis before and after each intervention.

HUI3, Health Utilities Index Mark 3. All interventions are described in Table 1. The trend in HUI3 may appear steep because the Y-axis range was restricted to better visualize the impact of interventions.</p

Descriptive data for the simulated population (base-case scenario).

Descriptive data for the simulated population (base-case scenario).</p

DALYs averted due to 8 interventions as a percentage of all OA-related DALYs, relative to base-case, over an 80-year time horizon.

DALYs, disability-adjusted life years. OA, osteoarthritis. All interventions are described in Table 1.</p

Description of the scenarios for inter-strategy comparisons.

Description of the scenarios for inter-strategy comparisons.</p

Total cumulative reductions in OA-related DALYs (DALYs averted) from 8 interventions in the simulated population.

DALYs, disability-adjusted life years. OA, osteoarthritis. All interventions are described in Table 1.</p

Use of four classes of analgesics before and after Medication x2 and Medication x3 interventions in people with osteoarthritis.

All interventions are described in Table 1.</p

Baseline sample characteristics in the follow-up sample (N = 122): N (%).

Baseline sample characteristics in the follow-up sample (N = 122): N (%).</p